2025 Annual Meeting | Industry Therapeutic Update form Eli Lilly and Company: AD in 3D An immersive tour of Alzheimer’s disease and modifiable risk factors

Date Monday 04/07/25

Time 06:00 PM - 08:00 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives Join us for an engaging evening dedicated to exploring Alzheimer’s disease (AD) through expert insights and an immersive experience. Enjoy dinner while hearing from a leading specialist on the AD continuum and how holistic health strategies can support cognitive wellness. Participate in an interactive visualization of the development of AD neuropathology, which can begin years prior to the development of symptoms and continues to build through the later stages of the AD continuum. Discover how management of modifiable risk factors can help change the course of care, and how you, as a provider, hold your patients’ future in your hands. This event offers a unique opportunity to deepen your understanding of AD, its impact, and potential approaches for reducing risk.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM PDT	Speaker	Industry Therapeutic Update form Eli Lilly and Company: AD in 3D An immersive tour of Alzheimer’s disease and modifiable risk factors

��ɫ��

��ɫ��